Get access to our best features
Get Started
SubscribeLogin
Get access to our best features
Get Started
Published

Solid Bio's former CEO launches new rare disease startup with €65M Series A

Summary by Endpoints News
A new startup aiming to tackle rare diseases de-stealthed Wednesday morning with a CEO experienced in the space. Alesta Therapeutics took the wraps off its €65 million Series A ($67 million) that it hopes to use for small molecule rare disease drug development.
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

StartupsStartups
LeidenLeiden
Dublin, IrelandDublin, Ireland
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2025 Snapwise Inc
News
For You
Search
BlindspotLocal